QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

$93.52
-0.45 (-0.48%)
(As of 02/26/2024 ET)
Today's Range
$92.58
$94.18
50-Day Range
$90.58
$112.35
52-Week Range
$88.00
$136.91
Volume
557,179 shs
Average Volume
688,146 shs
Market Capitalization
$22.23 billion
P/E Ratio
8.11
Dividend Yield
N/A
Price Target
$145.57

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
55.7% Upside
$145.57 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of BioNTech in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $4.96 to ($0.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

286th out of 942 stocks

Biological Products, Except Diagnostic Industry

39th out of 152 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
BioNTech (NASDAQ:BNTX) Coverage Initiated at BMO Capital Markets
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Cracking The Code: Understanding Analyst Reviews For BioNTech
BioNTech SE (NASDAQ:BNTX) Short Interest Update
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/26/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTX
Employees
4,530
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$145.57
High Stock Price Target
$260.00
Low Stock Price Target
$99.00
Potential Upside/Downside
+56.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$9.94 billion
Pretax Margin
52.86%

Debt

Sales & Book Value

Annual Sales
$18.24 billion
Cash Flow
$41.18 per share
Book Value
$87.07 per share

Miscellaneous

Free Float
192,074,000
Market Cap
$22.12 billion
Optionable
Optionable
Beta
0.27

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Prof. Ugur Sahin M.D. (Age 59)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $481.9k
  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $895.74k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $943.28k
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $990.82k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $478.66k
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $918.42k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
  • Sylke Maas Ph.D.
    Vice President of Investor Relations and Business Strategy
  • Michael Boehler
    MD & Head of Global External Communications
  • Dr. Oliver Hennig Ph.D.
    Senior Vice President of Operations

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Sunday, February 25, 2024 at 4:48 PM.














BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price target for 2024?

12 analysts have issued 1-year target prices for BioNTech's shares. Their BNTX share price targets range from $99.00 to $260.00. On average, they anticipate the company's share price to reach $145.57 in the next year. This suggests a possible upside of 55.7% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2024?

BioNTech's stock was trading at $105.54 at the beginning of the year. Since then, BNTX shares have decreased by 11.4% and is now trading at $93.52.
View the best growth stocks for 2024 here
.

Are investors shorting BioNTech?

BioNTech saw a decline in short interest in January. As of January 31st, there was short interest totaling 3,020,000 shares, a decline of 5.3% from the January 15th total of 3,190,000 shares. Based on an average trading volume of 694,100 shares, the days-to-cover ratio is presently 4.4 days. Currently, 1.3% of the company's shares are sold short.
View BioNTech's Short Interest
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) announced its quarterly earnings data on Monday, November, 6th. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $1.26. The company earned $895.30 million during the quarter, compared to the consensus estimate of $850.50 million. BioNTech had a net margin of 41.09% and a trailing twelve-month return on equity of 13.15%. The company's revenue was down 74.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $7.04 EPS.

What guidance has BioNTech issued on next quarter's earnings?

BioNTech issued an update on its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 2/26/2024 by MarketBeat.com Staff

From Our Partners